Background
In critically ill patients, infections can worsen rapidly and require immediate treatment before the exact cause is known. This is why clinicians often start empirical antimicrobial therapy, meaning antibiotics or other anti-infective drugs are given based on the most likely infection and local resistance patterns, rather than waiting for final culture results. The key question is whether the initial treatment actually covers the infecting organism. If it does, the therapy is considered appropriate. If it does not, the therapy is inappropriate and may lead to worse outcomes.
Although inappropriate antimicrobial therapy has long been linked with poor prognosis, the true size of the benefit from appropriate empiric therapy in ICU patients has not always been clear. This study from the DIANA dataset examined how often ICU patients with confirmed bacterial infections received appropriate initial treatment, and whether that treatment improved survival and reduced antimicrobial exposure.
Study Design
This was a predefined sub-analysis of the DIANA study, an international ICU cohort. Adult ICU patients who received empiric antimicrobials for suspected or confirmed bacterial infection were considered. For this analysis, only patients with microbiologically confirmed infections were included.
Therapy was classified as appropriate if at least one of the empirically administered antimicrobials showed in vitro activity against the identified pathogen. The investigators then examined associations with 28-day mortality, ICU mortality, and antimicrobial-free days, as well as mechanical ventilation-free days. Multivariable statistical models were used to adjust for important confounders. The study also explored whether the effect of appropriate therapy differed according to illness severity and diagnostic certainty.
Main Findings
A total of 845 patients with microbiologically confirmed infections were analyzed. Appropriate empiric antimicrobial therapy was given in 87.7% of cases, which suggests that empiric treatment strategies in this ICU cohort were often well aligned with the eventual microbiological diagnosis.
Patients who received appropriate therapy had better outcomes than those who received inappropriate therapy. Specifically, appropriate treatment was associated with lower ICU mortality and more days alive and free from antimicrobials over the following 28 days. They also had more mechanical ventilation-free days, indicating a broader clinical benefit beyond survival alone.
After multivariable adjustment, appropriate therapy remained independently associated with reduced 28-day mortality. In the study’s statistical models, the adjusted odds ratio was 1.83 with a 95% confidence interval of 1.11 to 3.06, and the hazard ratio was 1.51 with a 95% confidence interval of 1.03 to 2.21. These results were statistically significant and support the idea that getting the initial antimicrobial choice right matters in critically ill patients.
Effect of Disease Severity and Diagnostic Certainty
The authors also examined whether the benefit of appropriate therapy changed based on how sick the patient was or how certain the diagnosis was at the time treatment was started. The survival advantage of appropriate therapy was consistent across levels of diagnostic certainty. In other words, even when the initial diagnosis was less certain, appropriate empiric treatment still appeared beneficial if the infection was ultimately confirmed.
The benefit was most pronounced in patients with moderate illness severity, defined in this study by a SOFA score between 3 and 9. SOFA, or Sequential Organ Failure Assessment, is commonly used in critical care to estimate the extent of organ dysfunction. This finding may suggest that there is a particularly important window in moderately severe illness where timely effective empiric treatment can alter the clinical course before irreversible deterioration occurs.
Clinical Interpretation
These findings reinforce a central principle of critical care infectious disease management: early appropriate antimicrobial coverage is strongly associated with improved outcomes. In practical terms, this means that when a critically ill patient is suspected of having bacterial infection, clinicians should choose empiric therapy carefully based on likely pathogens, infection source, severity of illness, prior antibiotic exposure, local antibiograms, and risk factors for resistant organisms.
The results also support the importance of rapid diagnostic workup. Faster microbiological confirmation can help clinicians confirm whether the initial empiric regimen is appropriate and de-escalate therapy when possible. This matters not only for survival, but also for antimicrobial stewardship, because unnecessary broad-spectrum exposure increases the risk of antimicrobial resistance, drug toxicity, and secondary infections such as Clostridioides difficile.
Why Appropriate Empiric Therapy Matters
In the ICU, every hour can matter. Severe bacterial infections such as sepsis, pneumonia, bloodstream infection, or complicated intra-abdominal infection can progress quickly. If the first antimicrobial regimen does not cover the pathogen, the infection may continue unchecked while organ dysfunction worsens. Even when definitive therapy is later corrected, that delay can leave lasting harm.
Appropriate empiric therapy helps by reducing the time to effective treatment. This may limit bacterial proliferation, reduce inflammatory injury, and prevent progression to shock, respiratory failure, or multi-organ dysfunction. The association with more antimicrobial-free days in this study may also reflect faster clinical improvement and earlier narrowing or discontinuation of therapy.
Implications for ICU Practice
The study suggests several practical lessons for ICU teams:
First, empiric antibiotic selection should be individualized. No single regimen is right for all patients, and local resistance patterns are essential when choosing therapy.
Second, clinicians should recognize patients at high risk for resistant organisms, such as those with recent hospitalization, prior broad-spectrum antibiotic use, invasive devices, or known colonization with multidrug-resistant bacteria.
Third, antimicrobial stewardship remains crucial. Appropriate empiric therapy does not mean prolonged broad-spectrum use. Once microbiology results become available, therapy should be narrowed or stopped when appropriate.
Fourth, severity of illness matters. Patients with moderate severity may benefit especially from prompt effective treatment, suggesting that early optimization of therapy in this group may be a high-yield intervention.
Study Strengths and Limitations
A major strength of this analysis is its international ICU population and the relatively large sample of patients with microbiologically confirmed infections. The use of multivariable adjustment and effect-modification analyses also adds credibility to the findings.
However, some limitations should be kept in mind. This was an observational sub-analysis, so it cannot prove causation. Patients receiving inappropriate therapy may have differed in ways that also influenced outcomes, even after adjustment. In addition, therapy was defined as appropriate if at least one empiric agent had in vitro activity against the pathogen; this definition does not fully capture dose adequacy, tissue penetration, timing of administration, or whether combination therapy was clinically necessary. The study also focused on microbiologically confirmed infections, so the findings may not apply to all patients treated empirically in the ICU.
Conclusion
In this large international ICU analysis, appropriate empiric antimicrobial therapy was common and independently associated with improved 28-day survival. The benefit was seen across levels of diagnostic certainty and was most notable in patients with moderate illness severity. These results highlight the importance of choosing effective initial antimicrobial therapy in critically ill patients while maintaining a strong commitment to rapid diagnostics and antimicrobial stewardship.
